JohannChristophBrandesMDPhD, FCCP
Oncology • Murfreesboro, TNHematologic Oncology, Thoracic Cancer
Physician at Tennessee Oncology, Adjunct Assistant Professor, Hematology and Medical Oncology, Emory University School of Medicine
Dr. Brandes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1840 Medical Center Pkwy
Ste 300
Murfreesboro, TN 37129Phone+1 615-848-0488Fax+1 615-904-9061
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
- Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
Ruprecht Karls UniversityPhD, 2001
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1998
Certifications & Licensure
TN State Medical License 2014 - 2025
GA State Medical License 2009 - 2016
MD State Medical License 2003 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2013 Feb 13
Publications & Presentations
PubMed
- 6 citationsAndrogen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer.Kyungsuk Jung, Jong Chul Park, Hyunseok Kang, Johann C. Brandes
Epidemiology and Health. 2018-08-11 - 13 citationsSmall molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.Seth A. Brodie, Ge Li, R. Donald Harvey, Fadlo R. Khuri, Paula M. Vertino
Oncotarget. 2015-09-02 - 8 citationsMolecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.Seth A. Brodie, Ge Li, Johann C. Brandes
Respiratory Medicine. 2015-01-01
Press Mentions
Epilepsy Drug Lowers Head and Neck Cancer Risk by 34%February 10th, 2016
Grant Support
- CHFR as novel drug target to overcome taxane resistance in cancerElsa U Pardee Foundation2013–Present
- HDAC inhibition for Lung Cancer PreventionVHA Basic Laboratory Science Service2012–Present
- Can natural compounds augment the effects of HDAC inhibition for LC prevention?NIH2011–2012
- Targeting CHFR Through PARP-Inhibition: A Novel Strategy To Overcome Taxane Resistance in Adenocarcinomas of the LungUniting against Lung Cancer / Lungevity Foundation2009–2011
- Epigenetic predictors of response after platinum taxane based chemotherapy in NSCLCCHEST Foundation /Lungevity Foundation2009–2011
Committees
- Member, ACCP Thoracic Oncology Steering Commitee 2012 - Present
- Member, ECOG Cancer Prevention Commitee 2012 - Present
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
